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INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is a common,
serious complication in patients with cirrhosis and as-
cites. It is a bacterial infection of ascitic fluid in the ab-
sence of an adjacent, surgically amenable infection
source. Since its description in 1964 (1) numerous stud-
ies, guidelines, and both national and international con-
sensus conferences have brought significant advance-
ment to the diagnosis and treatment of this condition, and
significantly changed its prognosis (2-12). 
Initially considered a fatal complication of cirrhosis,
with mortality above 90%, the condition may be current-
ly treated with an in-hospital mortality rate around 20-
30% (13). However, it still is a highly relevant condition
in clinical practice given its high prevalence (it affects
10-30% of inpatients with cirrhosis and ascites), high re-
currence rate (up to 70% in the first year), and poor long-
term prognosis with mortality reaching 50-70% at one
year, which leads to consider patients recovering from
SBP potential candidates for liver transplantation (4-10).
PATHOPHYSIOLOGY 
The key pathogenic mechanism that starts SBP is bacte-
rial translocation (BT), a process by which both viable and
non-viable enteric bacteria, as well as their products (endo-
toxins, DNA), cross the intestinal mucosal barrier to infect
mesenteric lymph nodes, whence they enter the blood-
stream and then ascitic fluid (AF) (14). Patients with a re-
duced defensive capacity in their AF have been shown to
be more susceptible to peritonitis development (13).
All three major defense mechanisms preventing BT in
normal subjects are impaired during cirrhosis -intestinal
flora stability, intestinal epithelium integrity, and the
host’s immune defense (15). In advanced cirrhosis, in-
testinal motility is highly reduced because of sympathetic
nervous system hyperactivation, which leads to intestinal
bacterial overgrowth (16). Bacterial overgrowth has been
shown to favor BT (17). On the other hand, in patients
with advanced cirrhosis intestinal mucosal permeability
is increased, a direct consequence of portal hypertension
and local proinflammatory events mainly triggered by en-
dotoxin release (18). Lastly, defective local and systemic
defense mechanisms have been seen in cirrhotic patients:
neutrophile and macrophage phagocytosis is reduced, as
is the effector function of immunocompetent cells circu-
lating in the blood, which limits the bacteriostatic ability
of serum and AF (19). AF opsonization capacity is corre-
lated with total protein levels in AF. It is a well-estab-
lished fact that patients with reduced total proteins in AF
have a greater risk for SBP (20).
The on-and-off passage of bacterial products (endotox-
ins, bacterial DNA) into the systemic circulation leads to a
chronic inflammatory status characterized by persistent in-
nate immunity and cytokine synthesis activation (21). The
activation of the systemic immune-inflammatory system in
turn contributes to the worsened circulatory dysfunction
seen in cirrhosis. Circulating proinflammatory cytokines
such as TNF-  activate nitric oxide production thus favor-
ing peripheral vasodilation. The impact of BT also extends
to AF (22). Bacterial product (LPS, DNA) and proinflam-
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matory cytokine (IL-6, TNF- ) hyperproduction activates
peritoneal macrophages and the synthesis of proangiogenic
and vasodilator molecules (VEGF, nitric oxide). Finally, as
a consequence of arterial vasodilation endogenous vasoac-
tive systems become activated, and renal function is ulti-
mately impaired, which usually complicates the natural
course of SBP (23,24) (Fig. 1).
CLINICAL MANIFESTATIONS
The symptoms and signs of SBP are usually subtle,
hence a high index of suspicion is needed to prevent di-
agnostic delay, which entails a considerable worsening
of prognosis, especially in patients with a greater impair-
ment of liver function. Up to 13% of cases may be
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Fig. 1. Pathophysiology of SBP (PHT: portal hypertension; MLN: mesenteric lymph nodes; AF: ascitic fluid).
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asymptomatic (8,10). Clinical manifestations usually
consist of a worsening of symptoms commonly associat-
ed with cirrhosis, including increased ascites, diuretic
therapy failure, encephalopathy development or worsen-
ing, vomiting, etc. (13). Hence, when a cirrhotic patient
with ascites is admitted to hospital SBP should be
searched for even in the absence of obvious clinical
manifestations. Outside the hospital setting, SBP in cir-
rhotic patients with ascites is less common, occurs in pa-
tients with better liver function, and usually has a more
favorable prognosis (25). Whenever a cirrhotic patient
presents with temperature above 37.8 °C infection
should be ruled out (up to 68% of patients with SBP
have fever). Other common symptoms include abdomi-
nal pain and tenderness (present in 49% and 39% of pa-
tients with SBP, respectively), rebound sign (present in
10% of patients with SBP), and altered, often mildly,
mental state (in 54% of patients) (26). The development
of paralytic ileus, hypotension or hypothermia occurs in
advanced stages and entails a poorer prognosis. Labora-
tory changes such as leukocytosis, metabolic acidosis or
impaired renal function should always prompt the exclu-
sion of SBP, even in the absence of other clinical mani-
festations (8). 
DIAGNOSIS
Diagnostic paracentesis and cell count
The diagnosis of SBP is primarily based on the poly-
morphonuclear (PMN) count in AF as obtained using di-
agnostic paracentesis. SBP is established when PMN
numbers are equal to or greater than 250/µl in the absence
of a surgically amenable intra-abdominal infectious site.
This value enjoys high sensitivity, specificity, and diag-
nostic accuracy (4). Traditionally, neutrophil count in AF
was manually performed given the poor precision of au-
tomated counts regarding low neutrophil values in this
setting. However, a study demonstrated an excellent cor-
relation between both methods, hence automated counts
may well replace manual ones in the near future (27). In
the presence of hemorrhagic ascites (> 10,000 RBCs/µl),
one PMN must be subtracted per 250 red blood cells. To-
tal leukocytes in AF is useless in the diagnosis of SBP
(5,6). On the other hand, reactive strips used to assess
urine leukocytes have shown a lower sensitivity than
PMN counting for the diagnosis of SBP, and their use is
therefore discouraged (28,29). 
Other infection markers such as serum procalcitonin
and ascitic lactoferrin have proven useful for diagnostic
uncertainty, but further studies are needed before its use
may be recommended (30-32). Markers such as ascitic
pH or lactate were successfully used in some studies, but
have been discontinued as of today (33,34).
As mentioned above, diagnostic paracentesis is indi-
cated for all cirrhotic patients with ascites who are admit-
ted to hospital. Furthermore, it should always be per-
formed when a patient has: a) signs or symptoms sug-
gesting peritonitis, including abdominal pain, painful ab-
dominal decompression, and altered intestinal motility
(vomiting, diarrhea, ileus); b) evidence of systemic infec-
tion including temperature above 37.8 °C, peripheral
leukocytosis, or septic shock; c) impaired liver (hepatic
encephalopathy) or renal function; and d) digestive
bleeding before antibiotic prophylaxis onset (4-6,8).
Ascitic fluid cultures
In addition to cell counts, AF samples should be al-
ways obtained for culture. A positive culture is not neces-
sary for diagnosis given its low sensitivity because of low
bacterial levels in AF. At the time of paracentesis at least
10 mL should be inoculated into hemoculture bottles for
both aerobes and anaerobes, and promptly delivered to a
microbiology lab. In this way culture performance in this
setting has been increased to 50-70% of cases, and 90%
is reached in some studies (35-37).
In a high number of patients, hemocultures have been
seen to be positive and, since in such cases germs isolated
from peripheral blood are presumably those responsible
for SBP, samples for hemoculture should be always ob-
tained when SBP is suspected (38).
SBP variants
Neutrocytic ascites with negative culture
In this situation PMN count is ≥ 250/µl in AF but cul-
ture is negative. However, these patients have similar
signs, symptoms, and prognosis when compared to sub-
jects with SBP and positive AF culture. Therefore, “SBP
with negative culture” seems a more appropriate designa-
tion, as is also the case with other infections where no
causal germ is isolated and denominations or therapies
remain unchanged (38,39). Nevertheless, other causes of
increased neutrophils in AF should be excluded, includ-
ing peritoneal carcinomatosis, peritoneal tuberculosis,
hemorrhagic ascites, and pancreatitis (3).
Bacteriascites
It is characterized by bacterial AF colonization in the
absence of inflammatory response; PMN < 250/µl in AF
with a positive bacterial culture. Patients with bacteri-
ascites make up a heterogeneous population. Some pa-
tients suffer from spontaneous colonization while in
others colonization is secondary to extraperitoneal in-
fection. The natural history of untreated bacterioascites
is also variable, from spontaneous remission in over
60% of patients (particularly in asymptomatic subjects)
to the development of full-fledged SBP. Patients who
develop SBP usually have infection signs or symptoms
at the time of paracentesis (fever, abdominal pain, en-
cephalopathy), and should receive empiric antibiotics
pending AF culture results regardless of PMN count
(40).
A diagnosis of bacteriascites is reached at 2-3 days af-
ter paracentesis (time needed for culture growth).
Asymptomatic patients do not require immediate therapy,
and a repeat paracentesis with cell count and culture is
recommended on day 3, following which measures are to
be taken according to results obtained. When PMN count
in the second sample is ≥ 250/µl, antibiotics must be initi-
ated because of potential progression to SBP. If counts re-
main < 250/µl and cultures remain positive, antibiotic
therapy initiation is perhaps most recommended. If PMN
count remains < 250/µl and culture has become negative,
bacteriascites may be said to have spontaneously sub-
sided and no therapy is needed (5,6).
Secondary bacterial peritonitis
AF infection from visceral perforation or an abdomi-
nal organ abscess is designated secondary bacterial peri-
tonitis (SecBP). Clinical manifestations will not help in
differentiating patients with SBP —who only need antibi-
otics— from those with SecBP, who will need a surgical
procedure. 
We may suspect SecBP based on AF characteristics
when 2 or more of the following are identified: glucose
level <50 mg/dl, proteins > 1 g/dl, and LDH higher than
in plasma (26). However, the specificity of these criteria
is low, and the definition of other criteria has been there-
fore attempted to help in the differential diagnosis. Carci-
noembrionary antigen > 5 ng/ml in AF or alkaline phos-
phatase > 240 U/l in AF have been successfully used in
the diagnostic of peritonitis secondary to intestinal perfo-
ration with high sensitivity and specificity, although they
have proven useless when peritonitis does not result from
visceral perforation (41).
SecBP should also be suspected in cases of polymicro-
bial ascites after Gram staining or culture, particularly
when fungi, enterococcus, or anaerobes are identified. In
addition, when a patient diagnosed with SBP does not re-
spond to initial antibiotic therapy should SecBP be ruled
out.
In any patient with cirrhosis, ascites, and suspected
SecBP antibiotic therapy must cover anaerobes and ente-
rococci, and further studies with conventional X-rays, to-
mography and labeled-leukocyte scanning should be per-
formed (26,41) (Fig. 2).
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Fig. 2. Algorithm for the differential diagnosis between spontaneous and secondary bacterial peritonitis (modified from: Akriviadis EA, Runyon BA. The
value of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990; 98: 127-133) (PMN: polymorphonu-
clear; AF: ascitic fluid; TP: total proteins).
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TREATMENT
Antibiotic therapy
Empiric antibiotic therapy should be initiated immedi-
ately following the diagnosis with SBP, and then subse-
quently modified according to the antibiogram. The an-
tibiotic used must cover all germs commonly responsible
for SBP (3-6). Gram-negative bacteria cause nearly 80%
of events, primarily Escherichia coli and Klebsiella
pneumoniae. The remaining 20% results from Gram-pos-
itive aerobes, mainly Streptococcus species and entero-
cocci (42,43). Antibiotics should also reach adequate AF
levels. Third-generation cephalosporins are currently
considered the treatment of choice, cover 95% of isolated
germs, and clear infection in 77-98% of patients (44-46).
Cefotaxime at 2 g/12 hours has proven as effective as in
doses of 2 g/6 hours (47). Similarly, cefotaxime in doses
of 2 g/8 hours for 5 days is as effective as scheduled for
10 days (48). Other third-generation cephalosporins have
also been successful, including ceftriaxone and ceftazi-
dine (49-51). Amoxicillin plus clavulanic acid, first given
intravenously and then by mouth, has shown results simi-
lar to those of cefotaxime in a comparative study, albeit
with an inadequate number of patients (45). In patients
with allergy to -lactams quinolones may be used, includ-
ing intravenous ciprofloxacin (52-54). Aminoglycoside
and -lactam combinations have also been tried; however,
these are not more effective for infection clearance and
are associated with a high incidence of nephrotoxicity,
hence they are not recommended for the empiric manage-
ment of SBP (55). Despite the above, according to a re-
cent systematic review discussing thirteen studies, there
is no clear evidence yet on the optimal antibiotic, dose,
and duration that should be selected for treatment (56).
As a result of the widespread use of quinolones for the
prophylaxis of SBP in groups at risk, an increase in infec-
tions by Gram-negative germs resistant to quinolones and
gram-positive bacteria has been identified. However,
third-generation cephalosporins remain effective in the
management of SBP by said microorganisms, and data
available are inadequate to change recommendations in
this setting (43,57). In contrast, a recent study has shown
an increased frequency of infections by multiresistant
bacteria in cirrhotic inpatients, and fewer probabilities to
solve infection with the standard empiric therapy, this be-
ing why the authors suggest that extended-spectrum an-
tibiotics such as carbapenems and glycopeptides be in-
cluded in the empiric management of nosocomial
infection in cirrhotic patients (58). In another study
where 220 SBP events were analyzed, 23.6% were
caused by cefotaxime-resistant germs. Risk factors in-
cluded antibiotic use in the previous three months, pres-
ence of diabetes, and inpatient SBP episodes (59).
In patients with non-complicated SBP, that is, stable
patients with no GI bleeding, paralytic ileus, severe renal
failure signs (creatinine < 3 mg/dL) or severe hepatic en-
cephalopathy (grade < II) oral antibiotics may be indicat-
ed. In a multicenter, randomized, controlled study of such
selected patients oral ofloxacin 400 mg/12 hours for 8
days was as effective as conventional therapy with intra-
venous cefotaxime (46). Patients with non-complicated
SBP have also been successfully managed with oral
courses of cefixime (60) and ciprofloxacin (61), or with
IV therapy followed by oral amoxicillin-clavulanic acid
(47) or ciprofloxacin (53,54). 
Albumin overload
Up to 30% of patients with SBP develop impaired re-
nal function, which is the most relevant risk factor for in-
patient mortality (62). SBP results in functional renal in-
sufficiency because of a decrease in effective vascular
volume, which adds to the altered circulatory status of a
patient with advanced liver cirrhosis (62). In a controlled,
randomized trial in patients with SBP on cefotaxime, ex-
pansion using intravenous albumin (1.5 g/kg at diagnosis
and 1 g/kg on day 3) reduced the incidence of renal fail-
ure from 33 to 10%, and mortality from 29 to 10% (63).
An increase in effective intravascular volume seems the
primary mechanism through which albumin improves re-
nal function in these patients. However, whether volume
expansion is required for all patients or just those in the
subset with a higher risk for impaired renal function,
whether such expansion should be attempted with albu-
min or other plasma expanders, and whether doses as
high as those administered in this trial are necessary are
points that remain to be properly established (4). A recent
study concludes that albumin use should be restricted to
patients with severe liver failure (serum bilirubin > 4
mg/dl) or renal function impairment signs (BUN > 30
mg/dl or serum creatinine > 1 mg/dl) (64). In a recent re-
port albumin was superior to hydroxyethyl for plasma
volume expansion (65). In this study albumin improved
systemic hemodynamics by also targeting peripheral arte-
rial circulation through an increase in peripheral vascular
resistance. These authors suggest that albumin may have
an inhibitory effect on endothelial function.
Treatment response assessment
SBP is considered resolved when all local and sys-
temic signs are gone, PMN count in AF and PMN count
in peripheral blood are back to normal, and AF culture is
negative. In patients where infection persists mortality is
very high despite appropriate antibiotic therapy modifica-
tion (66,67). Early recognition of treatment failure and
timely therapy changes are crucial in these patients. To
this end infection must be followed up closely. Some
guidelines suggest the use of diagnostic paracentesis at
48 hours after antibiotic therapy initiation in order to con-
firm a reduced PMN count (a decrease inferior to 25% is
suggestive of poor response) (4-6). However, the latest
AASLD guidelines consider this measure unnecessary in
patients with no diagnostic uncertainties and positive in-
fection evolution (3). In case of negative progression the
initial antibiotic should be changed (under antibiogram
guidance if possible), and secondary bacterial peritonitis
should be excluded.
PROPHYLAXIS
The frequency of SBP in cirrhotic patients and the high
morbidity and mortality associated with this condition
warrant the use of prophylactic measures. Since the pri-
mary mechanism of infection is the BT of Gram-nega-
tive, enteric germs, antibiotics should provide selective
intestinal decontamination, that is, a clearance of the
gram-negative flora while preserving anaerobes. Howev-
er, the high cost and risk of bacterial resistance develop-
ment restricts prophylaxis to high-risk groups (68). Three
categories of cirrhotic patients with ascites and higher
risk for SBP have been identified -patients with no prior
SBP and low proteins in AF and/or increased serum
bilirubin (primary prophylaxis), patients who survived a
previous SBP episode (secondary prophylaxis), and inpa-
tients with GI bleeding.
Primary prophylaxis
Patients with low protein levels in AF and/or high
serum bilirubin have a higher risk for SBP. The probabili-
ty of a first SBP episode in patients with serum bilirubin
higher than 2.5 mg/dl was up to 43% in one study (69). In
other study 15% of patients with AF proteins below 10
g/l developed SBP during their hospital stay (70). When
protein levels are high in AF (> 15 g/l) the risk for SBP is
negligible and antibiotic prophylaxis is considered un-
necessary (70-72). While no clear scientific evidence al-
lows recommendations for patients with AF protein lev-
els lower than 15 g/l, some studies suggest that antibiotic
prophylaxis might be an appropriate strategy (73-77).
The antibiotic used in most studies is norfloxacin 400
mg/day continuously (73-75,77). In a controlled, ran-
domized study (77) patients with low AF proteins (< 15
g/l), advanced liver failure (Child-Pugh ≥ 9, bilirubin ≥ 3
mg/dl) or impaired renal function (creatinine ≥ 1.2 mg/dl,
BUN ≥ 25 mg/dl, serum sodium ≤ 130 mEq/l) receiving
norfloxacin were less likely to develop SBP (7 vs. 61%)
and hepatorenal syndrome (28 vs. 41%) after one year,
and showed higher survival at 3 months (94 vs. 62%)
when compared to patients receiving no antibiotic pro-
phylaxis. Other antibiotics used in the primary prophy-
laxis of SBP include ciprofloxacin 500 mg/day (76) and
trimethoprim-sulfamethoxazole 160/800 mg 5 days/week
(78,79). Most recent clinical guidelines recommend an-
tibiotic prophylaxis for SBP in these high-risk patients,
preferably in a continuous schedule and not only during
hospital admissions (3,4). However, available data are in-
sufficient to recommend antibiotic prophylaxis for all pa-
tients on liver transplant waiting lists (3).
Secondary prophylaxis
Patients recovering from a SBP episode have an annu-
al relapse probability of up to 70% (2). The use of antibi-
otic prophylaxis is widely established in these patients (3-
10). There is only one controlled study of norfloxacin in
patients who recovered from an SBP event where the
probability of SBP relapse decreased from 68 to 20% in
patients receiving antibiotic prophylaxis with norfloxacin
(400 mg/24 hours, PO) (80). Other studies evaluating
norfloxacin (73), ciprofloxacin 750 mg/week (81) or
trimethoprim-sulfamethoxazole 160-800 mg 5 days/week
(78,79) included patients with and without prior SBP.
Daily dosing schedules have proven superior to intermit-
tent schedules as the latter select bacterial resistance with
a higher frequency (82). 
Assessing liver transplantation is important in patients
recovering from SBP given its poor prognosis (83,84).
When liver function improves and ascites disappears,
whether prophylaxis should be maintained indefinitely or
discontinued is not clear (4,5).
Prophylaxis in cirrhotic patients with GI bleeding
Bacterial infection is a common issue in cirrhotic pa-
tients with acute GI bleeding -up to 20% are infected at
admission and around 50% become infected during their
hospital stay (85-94). In addition, infection risk has been
shown to be higher in patients with advanced cirrhosis
and severe GI bleeding (91,92,95). On the other hand, the
presence of infection aggravates prognosis in these pa-
tients by increasing the risk of hepatorenal syndrome,
failed bleeding management, and rebleed chances, and
ultimately by increasing inpatient mortality (92,95). A
meta-analysis of 5 studies of antibiotic prophylaxis in
these patients concludes that antibiotics are effective for
the prevention of bacterial infection, which is associated
with significantly improved survival (by 9.1% in the
treated group) (92). According to a prospective, random-
ized study, norfloxacin 400 mg/12 hours PO or via a na-
sogastric tube for 7 days prevents bacterial infection,
specifically SBP, in cirrhotic patients with gastrointesti-
nal bleeding (87). Intravenous ofloxacin may be used
during active bleeding (88). However, the changes seen
in recent years in the epidemiology of bacterial infection
in patients with cirrhosis, with an increase in quinolone-
resistant Gram-negative bacilli, and a high frequency of
infection by Gram-positive germs in association with in-
vasive endoscopic procedures have led some authors to
reconsider antibiotic therapy (43,95). In a recent study in
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patients with GI bleeding and advanced cirrhosis (at least
2 of the following: ascites, severe malnutrition, en-
cephalopathy, or bilirubin > 3 mg/dl), ceftriaxone 1 g/24
hours was more effective than norfloxacin (400 mg/12
hours) for the prevention of infection and SBP (11 versus
33%, and 2 versus 12%, respectively) (95).
CONCLUSION
SBP is a common, serious complication in patients
with advanced liver cirrhosis and ascites. Early diagnosis
and treatment have improved prognosis in the last few
years. However, its poor long-term prognosis leads to
consider liver transplantation for patients recovering
from a SBP episode.
Diagnosis requires a high index of suspicion given
that, on occasion, SBP develops insidiously, which ren-
ders diagnostic paracentesis mandatory for all cirrhotic
patients with ascites and signs or symptoms of infection,
GI bleeding, or worsening renal or liver function, and
even for asymptomatic inpatients. Once a diagnosis is
reached based on elevated AF PMN counts, empiric an-
tibiotic therapy should be initiated early using intra-
venous third-generation cephalosporins for seriously ill
patients. For patients with no renal or liver failure evi-
dence and good digestive tolerance oral antibiotics may
be used, including quinolones and amoxicillin-clavu-
lanate. In addition, in selected cases with high risk of re-
nal failure the addition of volume expansion using intra-
venous albumin may be recommended. Preventive
treatment is indicated for patients with a higher risk of
developing SBP -those who recovered from a previous
episode, subjects with GI bleeding, and selected individu-
als with low AF protein levels and/or elevated serum
bilirubin.
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